 |
|
Babies born prematurely or with health problems are most susceptible to a
variety of serious and even fatal diseases. Clinical research studies prove that human breast
milk has the ability to improve gastrointestinal function, immunological
defenses, uptake and retention of nutrients, and better the neurodevelopment of an
infant. Without human milk, these already defenseless babies are even more
vulnerable to necrotizing enterocolitis, sepsis and feeding intolerance.
Prolacta Bioscience
provides pharmaceutical grade specialty formulations of human milk to ensure
that every premature and critically-ill baby receives all the benefits that only
natural human milk can offer. The company has developed improved methods for
testing, formulating and processing human milk to ensure only the highest
quality milk is distributed to the babies during this vulnerable period.
Prolacta collects breast milk from collection centers, purifies it, formulates
it and then distributes it directly to the neonatal intensive care units (NICU)
of hospitals.
Funk Ventures Capital Partners made its first
investment in Prolacta during the company's 2006 $5 million Series B financing, which included syndicate partners Arcturus Capital, DFJ Frontier
and DFJ Mercury.
|
